Gilead Sciences (NASDAQ:GILD), a leading biopharmaceutical company, has today outlined plans to create $43 billion in value for the U.S. economy over the next five years through direct capital investment and job creation. The latest initiative will further grow the company’s presence in the U.S., which currently hosts Gilead’s largest research, development, and manufacturing footprint globally.

Advertisement: High Yield Savings Offers

Earn up to 4.35% APY** with $5k balance  View Offer

Earn up to 4.00% APY with Savings Pods  View Offer

Earn up to 3.80% APY¹ & up to $300 Cash Bonus with Direct Deposit  View Offer

Powered by Money.com - Yahoo may earn commission from the links above.

The investment includes a fresh allocation of $11 billion for capital and operational expenditures in the U.S. This is in addition to a previously planned spend of $21 billion aimed at U.S. manufacturing and research & development through 2030. The combined investment is projected to generate an extra $11 billion in U.S. economic impact.

Gilead’s forthcoming investment phase will finance the construction of three new advanced facilities, the upgrade of three existing sites to extend U.S. manufacturing and R&D capabilities, and the investment in new technology and advanced engineering initiatives. The additional $11 billion breaks down as follows:

- $4 billion for capital projects, including labs and equipment.
- $5 billion for technology, operations, and R&D site activities.
- $2 billion for digital and advanced engineering initiatives.

Furthermore, the investment is set to create approximately 800 new direct jobs and support over 2,200 indirect jobs by 2028. This move continues Gilead’s long-standing history of U.S. investment, having invested $15 billion over the past decade. It also underscores Gilead’s significant role in the U.S. biopharmaceutical industry, contributing to scientific innovation and providing solutions for patients.

Related articles

Gilead Sciences to invest $11 billion in U.S. R&D and manufacturing

Charles River to initiate a review amid Elliott stake - Is a sale next?

Discover Financial Services lowered to Hold at Jefferies

View Comments